HIV-specific ADCC improves after antiretroviral therapy and correlates with normalization of the NK cell phenotype

Journal of Acquired Immune Deficiency Syndromes

Volumn 68, Issue 2, 2015, Pages 103-111

  Jensen, Sanne S ^a,b   Hartling, Hans J ^c   Tingstedt, Jeanette L ^a   Larsen, Tine K ^a   Nielsen, Susanne D ^c   Pedersen, Court ^b   Fomsgaard, Anders ^a,b   Karlsson, Ingrid ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

antibody dependent cellular cytotoxicity; antiretroviral therapy; Natural killer cell; NK cell phenotype; NK cell subsets

Indexed keywords

ATAZANAVIR; BETA3 INTEGRIN; CD27 ANTIGEN; CD56 ANTIGEN; CHEMOKINE RECEPTOR CCR7; DARUNAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; TENOFOVIR DISOPROXIL; ANTIRETROVIRUS AGENT; CCR7 PROTEIN, HUMAN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CELL MATURATION; CELL SUBPOPULATION; CELLULAR DISTRIBUTION; CORRELATION ANALYSIS; DOWN REGULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; ADULT; AGED; CHEMISTRY; FEMALE; HIV INFECTIONS; IMMUNOLOGY; IMMUNOPHENOTYPING; LONGITUDINAL STUDY; MALE; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD27; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNOPHENOTYPING; KILLER CELLS, NATURAL; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RECEPTORS, CCR7; YOUNG ADULT;

EID: 84922482386     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000429     Document Type: Article

References (32)

1. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity The example of natural killer cells. Science. 2011;331:44-49.
2. Fauci AS, Mavilio D, Kottilil S. NK cells in HIV infection: paradigm for protection or targets for ambush. Nat Rev Immunol. 2005;5:835-843.
3. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366:1275-1286.
4. Paiardini M, Muller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev. 2013;254:78-101.
5. Bisio F, Bozzano F, Marras F, et al. Successfully treated HIV-infected patients have differential expression of NK cell receptors (NKp46 and NKp30) according to AIDS status at presentation. Immunol Lett. 2013;152:16-24.
6. Alter G, Teigen N, Davis BT, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood. 2005;106:3366-3369.
7. Milush JM, Lopez-Verges S, York VA, et al. CD56negCD16(+) NK cells are activated mature NK cells with impaired effector function during HIV-1 infection. Retrovirology. 2013;10:158.
8. Titanji K, Sammicheli S, De Milito A, et al. Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic human immunodeficiency virus-1 infection. Immunology. 2008;123:164-170.
9. Naranbhai V, Altfeld M, Karim SS, et al. Changes in natural killer cell activation and function during primary HIV-1 Infection. PLoS One. 2013;8:e53251.
10. Mavilio D, Lombardo G, Benjamin J, et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA. 2005;102: 2886-2891.
11. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007;449:101-104.
12. Focosi D, Bestagno M, Burrone O, et al. CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol. 2010;87:107-116.
13. Lopez-Verges S, Milush JM, Pandey S, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood. 2010;116:3865-3874.
14. Chattopadhyay PK, Betts MR, Price DA, et al. The cytolytic enzymes granyzme A, granzyme B, and perforin: expression patterns, cell distribution, and their relationship to cell maturity and bright CD57 expression. J Leukoc Biol. 2009;85:88-97.
15. Vossen MT, Matmati M, Hertoghs KM, et al. CD27 defines phenotypically and functionally different human NK cell subsets. J Immunol. 2008;180:3739-3745.
16. Silva A, Andrews DM, Brooks AG, et al. Application of CD27 as a marker for distinguishing human NK cell subsets. Int Immunol. 2008;20:625-630.
17. Fehniger TA, Cooper MA, Nuovo GJ, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cellderived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003;101:3052-3057.
18. De Maria A, Fogli M, Costa P, et al. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol. 2003;33:2410-2418.
19. Weber K, Meyer D, Grosse V, et al. Reconstitution of NK cell activity in HIV-1 infected individuals receiving antiretroviral therapy. Immunobiology. 2000;202:172-178.
20. Chehimi J, Azzoni L, Farabaugh M, et al. Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment. J Immunol. 2007;179:2642-2650.
21. Howell DN, Andreotti PE, Dawson JR, et al. Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. J Immunol. 1985;134:971-976.
22. Pollara J, Hart L, Brewer F, et al. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A. 2011;79:603-612.
23. Borggren MVL, Andresen BS, Grevstad B, et al, Fomsgaard a optimization of HIV-1 envelope DNA vaccine candidates within three different animal models, guinea pigs, rabbits and cynomolgus macaques. Vaccines. 2013;1:305-327.
24. Montaldo E, Del Zotto G, Della Chiesa M, et al. Human NK cell receptors/markers: a tool to analyze NK cell development, subsets and function. Cytometry A. 2013;83:702-713.
25. Bayigga L, Nabatanzi R, Sekiziyivu PN, et al. High CD56++CD16-natural killer (NK) cells among suboptimal immune responders after four years of suppressive antiretroviral therapy in an African adult HIV treatment cohort. BMC Immunol. 2014;15:2.
26. Hong HS, Ahmad F, Eberhard JM, et al. Loss of CCR7 expression on CD56(bright) NK cells is associated with a CD56(dim)CD16(+) NK cell-like phenotype and correlates with HIV viral load. PLoS One. 2012;7:e44820.
27. Parsons MS, Tang CC, Jegaskanda S, et al. Anti-HIV antibodydependent activation of NK cells impairs NKp46 expression. J Immunol. 2014;192:308-315.
28. Ljunggren K, Broliden PA, Morfeldt-Manson L, et al. IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages. Clin Exp Immunol. 1988;73:343-347.
29. Norley SG, Mikschy U, Werner A, et al. Demonstration of crossreactive antibodies able to elicit lysis of both HIV-1-and HIV-2-infected cells. J Immunol. 1990;145:1700-1705.
30. Lambotte O, Pollara J, Boufassa F, et al. High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers. PLoS One. 2013;8:e74855.
31. Kottilil S, Shin K, Jackson JO, et al. Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions. J Immunol. 2006; 176:1107-1114.
32. Chung AW, Rollman E, Center RJ, et al. Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol. 2009; 182:1202-1210.